Evidence map›Paper›PMID 39816023›Full record

ArticleJournal of gastrointestinal oncology2024

Mismatch repair deficiency confers worse survival in stage IV colon cancer.

David Schaub, Joseph Gunderson, Sierra Thompson, Sabina Saeed, Elisabeth Batzli, Rohan Mittal, Daniom Tecle, Katherine Pavleszek, Valentine Nfonsam

Abstract read
In one paragraph

Article in Journal of gastrointestinal oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

David SchaubDepartment of Surgery, University of Arizona College of Medicine-Tucson, Tucson, Arizona, USA.ORCID https://orcid.org/0000-0002-7226-0157
Joseph GundersonDepartment of Surgery, University of Arizona College of Medicine-Tucson, Tucson, Arizona, USA.
Sierra ThompsonDepartment of Surgery, A.T. Still University School of Osteopathic Medicine, Mesa, Arizona, USA.
Sabina SaeedDepartment of Surgery, University of Arizona College of Medicine-Tucson, Tucson, Arizona, USA.
Elisabeth BatzliDepartment of Surgery, University of Arizona College of Medicine-Tucson, Tucson, Arizona, USA.
Rohan MittalDepartment of Surgery, University of Arizona College of Medicine-Tucson, Tucson, Arizona, USA.
Daniom TecleDepartment of Surgery, University of Arizona College of Medicine-Tucson, Tucson, Arizona, USA.
Katherine PavleszekDepartment of Surgery, Louisiana State University Health Sciences Center School of Medicine, New Orleans, LA, USA.
Valentine NfonsamDepartment of Surgery, Louisiana State University Health Sciences Center School of Medicine, New Orleans, LA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Metastatic colon cancer (MCC) is a debilitating condition with a poor prognosis. Currently, there is limited data that investigates MCC in relation to mismatch repair (MMR) status. The aims of this study are to compare sociodemographic and clinicopathologic features and mortality between patients with MMR-proficient (MMR-P) and MMR-deficient (MMR-D) MCC. Methods: We performed an 8-year retrospective review of the National Cancer Database (NCDB) to identify patients age ≥18 years with MCC and reported MMR status. Data collection included sociodemographic characteristics, primary tumor sites and histopathologic features, and treatment modalities. Outcomes included 90-day, 180-day, 1-year, and 2-year overall mortality. Bivariate logistic regression and multivariate Cox regression identified differences between MMR-P and MMR-D and identified predictors of mortality, respectively. Results: A total of 10,922 MCC cases were identified; 8,796 (80.53%) were MMR-P and 2,126 (19.47%) were MMR-D. MMR-D was independently associated with older age at diagnosis, female sex, mucinous adenocarcinoma, medullary carcinoma, and lymph-vascular invasion. MMR-P was independently associated with perineural invasion and left-sided colonic primary tumor predominance. When adjusted for demographics, histology, and treatment modalities, MMR-D was associated with mortality at 180 days, 1 year, and 2 years. Conclusions: Our study identified several key sociodemographic and clinicopathologic features of MMR-D MCC. MMR-D appears to confer increased overall mortality at 180 days, 1 year, and 2 years after diagnosis in MCC.

Indexed as

clinical outcomesMetastatic colon cancer (MCC)mismatch repair (MMR)

Identifiers

PMID39816023
PMCPMC11732351

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.